Eliquis Gets NICE Final Nod But Fails to Outrun The Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has cleared a path for Bristol-Myers Squibb’s Eliquis to be included on the British National Health System, but said the data supplied were not robust enough to differentiate the drug from its competition.